Browsing Radiotherapy and Imaging by author "Huddart, Robert"
Now showing items 21-40 of 106
-
Comparison of prostate delineation on multimodality imaging for MR-guided radiotherapy.
Pathmanathan, AU; McNair, HA; Schmidt, MA; Brand, DH; Delacroix, L; et al. (BRITISH INST RADIOLOGY, 2019-03-01)OBJECTIVE:: With increasing incorporation of MRI in radiotherapy, we investigate two MRI sequences for prostate delineation in radiographer-led image guidance. METHODS:: Five therapeutic radiographers contoured the prostate ... -
Controversies in the management of clinical stage 1 testis cancer.
Nason, GJ; Chung, P; Warde, P; Huddart, R; Albers, P; et al. (CANADIAN UROLOGICAL ASSOCIATION, 2020-11-01)<jats:p>In November 2018, The Canadian Testis Cancer Workshop was convened. The two-day workshop involved urologists, medical and radiation oncologists, pathologists, radiologists, physician’s assistants, residents and ... -
Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.
Kerns, SL; Fung, C; Monahan, PO; Ardeshir-Rouhani-Fard, S; Abu Zaid, MI; et al. (AMER SOC CLINICAL ONCOLOGY, 2018-05-20)Purpose In this multicenter study, we evaluated the cumulative burden of morbidity (CBM) among > 1,200 testicular cancer survivors and applied factor analysis to determine the co-occurrence of adverse health outcomes (AHOs). ... -
Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma.
Gilbert, DC; Al-Saadi, R; Thway, K; Chandler, I; Berney, D; et al. (AMER ASSOC CANCER RESEARCH, 2016-03-01)PURPOSE: Up to 50% of patients diagnosed with stage I nonseminomatous germ cell tumors (NSGCTs) harbor occult metastases. Patients are managed by surveillance with chemotherapy at relapse or adjuvant treatment up front. ... -
Diffusion-weighted MRI to determine response and long-term clinical outcomes in muscle-invasive bladder cancer following neoadjuvant chemotherapy.
Hafeez, S; Koh, M; Jones, K; Ghzal, AE; D'Arcy, J; et al. (FRONTIERS MEDIA SA, 2022-11-14)OBJECTIVE: This study aims to determine local treatment response and long-term survival outcomes in patients with localised muscle-invasive bladder cancer (MIBC) patients receiving neoadjuvant chemotherapy (NAC) using ... -
Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer.
Tree, AC; Jones, K; Hafeez, S; Sharabiani, MTA; Harrington, KJ; et al. (ELSEVIER SCIENCE INC, 2018-08-01)There is currently significant interest in the potential benefits of combining radiation and immune checkpoint blockade (ICB) to stimulate both regional and distant abscopal immune responses. In melanoma and lung cancer, ... -
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Siefker-Radtke, AO; Necchi, A; Park, SH; García-Donas, J; Huddart, RA; et al. (ELSEVIER SCIENCE INC, 2022-02-01)BACKGROUND: Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, was shown to be clinically active and tolerable in patients with advanced urothelial carcinoma and prespecified FGFR ... -
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
Loriot, Y; Necchi, A; Park, SH; Garcia-Donas, J; Huddart, R; et al. (MASSACHUSETTS MEDICAL SOC, 2019-07-25)BACKGROUND: Alterations in the gene encoding fibroblast growth factor receptor (FGFR) are common in urothelial carcinoma and may be associated with lower sensitivity to immune interventions. Erdafitinib, a tyrosine kinase ... -
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.
Dearnaley, DP; Jovic, G; Syndikus, I; Khoo, V; Cowan, RA; et al. (ELSEVIER SCIENCE INC, 2014-04-01)BACKGROUND: The aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose conformal radiotherapy in patients with localised prostate cancer. Preliminary findings reported after 5 years of ... -
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.
Honecker, F; Aparicio, J; Berney, D; Beyer, J; Bokemeyer, C; et al. (OXFORD UNIV PRESS, 2018-08-01)The European Society for Medical Oncology (ESMO) consensus conference on testicular cancer was held on 3-5 November 2016 in Paris, France. The conference included a multidisciplinary panel of 36 leading experts in the ... -
Evaluation of non-vendor magnetic resonance imaging sequences for use in bladder cancer magnetic resonance image guided radiotherapy.
Chick, J; Alexander, S; Herbert, T; Huddart, R; Ingle, M; et al. (ELSEVIER, 2023-07-01)Hybrid systems that combine Magnetic Resonance Imaging (MRI) and linear accelerators are available clinically to guide and adapt radiotherapy. Vendor-approved MRI sequences are provided, however alternative sequences may ... -
Exploration of the treatment challenges in men with intellectual difficulties and testicular cancer as seen in Down syndrome: single centre experience.
Hafeez, S; Singhera, M; Huddart, R (BMC, 2015-06-26)Down syndrome is the most common chromosomal disorder in humans as well as the most common cause of inherited intellectual disability. A spectrum of physical and functional disability is associated with the syndrome as ... -
Failing to Close the Gap Between Evidence and Clinical Practice in Radical Bladder Cancer Radiotherapy.
Hafeez, S; Lewis, R; Griffin, C; Hall, E; Huddart, R (ELSEVIER SCIENCE LONDON, 2021-01-01) -
Feasibility of magnetic resonance guided radiotherapy for the treatment of bladder cancer.
Hunt, A; Hanson, I; Dunlop, A; Barnes, H; Bower, L; et al. (ELSEVIER IRELAND LTD, 2020-11-01)Whole bladder magnetic resonance image-guided radiotherapy using the 1.5 Telsa MR-linac is feasible. Full online adaptive planning workflow based on the anatomy seen at each fraction was performed. This was delivered within ... -
Feasibility of tumour-focused adaptive radiotherapy for bladder cancer on the MR-linac.
Mitchell, A; Ingle, M; Smith, G; Chick, J; Diamantopoulos, S; et al. (ELSEVIER IRELAND LTD, 2022-07-01)Bladder tumour-focused magnetic resonance image-guided adaptive radiotherapy using a 1.5 Tesla MR-linac is feasible. A full online workflow adapting to anatomy at each fraction is achievable in approximately 30 min. ... -
Features and Management of Late Relapse of Nonseminomatous Germ Cell Tumour.
Jay, APM; Aldiwani, M; O'Callaghan, ME; Pearce, AK; Huddart, RA; et al. (ELSEVIER, 2021-06-07)BACKGROUND: Late relapse (LR) of nonseminomatous germ cell tumour (NSGCT) is uncommon, with limited data published. LR is defined as relapse occurring after a disease-free interval of 2 yr. OBJECTIVE: To review features ... -
From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
Hussain, SA; Birtle, A; Crabb, S; Huddart, R; Small, D; et al. (ELSEVIER, 2018-12-01)CONTEXT: A number of PD-1/PD-L1 inhibitors have recently been approved for use in patients with locally advanced or metastatic urothelial carcinoma (UC) on the basis of results from several clinical trials. OBJECTIVE: To ... -
Genomic landscape of platinum resistant and sensitive testicular cancers.
Loveday, C; Litchfield, K; Proszek, PZ; Cornish, AJ; Santo, F; et al. (NATURE PUBLISHING GROUP, 2020-05-04)While most testicular germ cell tumours (TGCTs) exhibit exquisite sensitivity to platinum chemotherapy, ~10% are platinum resistant. To gain insight into the underlying mechanisms, we undertake whole exome sequencing and ... -
Histological Features of Sporadic and Familial Testicular Germ Cell Tumors Compared and Analysis of Age-Related Changes of Histology.
Stang, A; McMaster, ML; Sesterhenn, IA; Rapley, E; Huddart, R; et al. (MDPI, 2021-04-01)This study aimed to compare histological features of familial and sporadic testicular germ cell tumors (TGCTs) and surrounding parenchyma, since discriminating features might be etiologically relevant and clinically useful. ... -
Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials.
Choudhury, A; Porta, N; Hall, E; Song, YP; Owen, R; et al. (ELSEVIER SCIENCE INC, 2021-02-01)BACKGROUND: Two radiotherapy fractionation schedules are used to treat locally advanced bladder cancer: 64 Gy in 32 fractions over 6·5 weeks and a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks. Long-term ...